Susan Tsai, Mhs

List of Publications by Year
in descending order

122 papers	2,999 citations	186209 28 h-index	182361 51 g-index
124 all docs	124 docs citations	124 times ranked	5017 citing authors

#	Article	IF	Citations
1	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. Modern Pathology, 2022, 35, 96-105.	2.9	13
2	Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2022, 275, e229-e237.	2.1	14
3	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 589-589.	0.8	1
4	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. Journal of Clinical Oncology, 2022, 40, 474-474.	0.8	0
5	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. Journal of Clinical Oncology, 2022, 40, 596-596.	0.8	0
6	Trading up: Balancing centralization and its trade-offs. American Journal of Surgery, 2022, , .	0.9	1
7	Lessons learned from investigatorâ€initiated clinical trials for localized pancreatic cancer. Journal of Surgical Oncology, 2022, 125, 69-74.	0.8	2
8	Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?. Journal of Surgical Research, 2022, 278, 31-38.	0.8	1
9	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, e16260-e16260.	0.8	2
10	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16281-e16281.	0.8	0
11	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 2246-2256.	0.7	29
12	Moving Toward a More Informed Approach to Risk Stratification of Patients: Comments on Seror et al. CT-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related HCC. Annals of Surgical Oncology, 2021, 28, 24-26.	0.7	0
13	Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery, 2021, 169, 629-635.	1.0	2
14	Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Clinical Cancer Research, 2021, 27, 226-236.	3.2	15
15	Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Frontiers in Oncology, 2021, 11, 606820.	1.3	4
16	Tenâ€year experience in optimizing neoadjuvant therapy for localized pancreatic cancerâ€"Medical college of Wisconsin perspective. Journal of Surgical Oncology, 2021, 123, 1405-1413.	0.8	4
17	Precision Medicine for Pancreatic Cancer. Advances in Oncology, 2021, 1, 63-71.	0.1	0
18	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. American Journal of Surgery, 2021, 222, 10-17.	0.9	41

#	Article	IF	Citations
19	EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. Clinical Cancer Research, 2021, 27, 6135-6144.	3.2	26
20	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 657-671.	0.6	0
21	Updates on the Management of Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, xvii-xviii.	0.6	3
22	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. Annals of Surgical Oncology, 2021, 28, 1457-1465.	0.7	17
23	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. Cancers, 2021, 13, 5204.	1.7	13
24	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer and Metastasis Reviews, 2021, 40, 879-889.	2.7	2
25	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	0.8	17
26	Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. , 2021, , .		0
27	Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Annals of Surgery, 2020, 271, 740-747.	2.1	127
28	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Annals of Surgical Oncology, 2020, 27, 85-97.	0.7	22
29	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. Annals of Surgical Oncology, 2020, 27, 1156-1163.	0.7	7
30	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242.	0.9	6
31	Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. Journal of Gastrointestinal Oncology, 2020, 11, 548-558.	0.6	18
32	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. Hpb, 2020, 22, 1675-1685.	0.1	10
33	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery, 2020, 168, 760-767.	1.0	2
34	Black raspberries suppress pancreatic cancer through modulation of NKp46⁺, CD8⁺, and CD11b⁺ immune cells. Food Frontiers, 2020, 1, 70-82.	3.7	11
35	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. Journal of Surgical Oncology, 2020, 122, 176-182.	0.8	7
36	Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology, 2020, 10, 553.	1.3	74

#	Article	IF	Citations
37	Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Annals of Diagnostic Pathology, 2020, 46, 151485.	0.6	6
38	Outcomes of palliativeâ€intent surgery in retroperitoneal sarcomaâ€"Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	0.8	7
39	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery, 2020, 168, 440-447.	1.0	15
40	p38Î³ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. Cancer Research, 2020, 80, 3251-3264.	0.4	47
41	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 460.	1.3	20
42	Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene, 2020, 39, 4257-4270.	2.6	22
43	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Hpb, 2020, 22, 1745-1752.	0.1	2
44	Black Raspberries Suppress Colorectal Cancer by Enhancing Smad4 Expression in Colonic Epithelium and Natural Killer Cells. Frontiers in Immunology, 2020, 11, 570683.	2.2	12
45	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	0.8	6
46	Has Personalized Medicine for Pancreatic Cancer Arrived?. Advances in Surgery, 2019, 53, 103-115.	0.6	6
47	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 2019, 166, 277-285.	1.0	40
48	A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. Npj Precision Oncology, 2019, 3, 25.	2.3	98
49	Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 4515-4521.	0.7	7
50	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. Journal of Surgical Research, 2019, 240, 130-135.	0.8	13
51	Molecular Characteristics of Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 685-693.	0.6	6
52	Distal splenorenal and mesocaval shunting at the time of pancreatectomy. Surgery, 2019, 165, 298-306.	1.0	14
53	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2019, 228, 245-254.	0.2	8
54	Elective Regional Therapy Treatment for Hepatic Adenoma. Annals of Surgical Oncology, 2019, 26, 125-130.	0.7	10

#	Article	IF	Citations
55	A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 680-689.	1.1	2
56	Improving Treatment Response Prediction for Chemoradiation Therapy of Pancreatic Cancer Using a Combination of Delta-Radiomics and the Clinical Biomarker CA19-9. Frontiers in Oncology, 2019, 9, 1464.	1.3	38
57	Ablation approach for primary liver tumors: Periâ€operative outcomes. Journal of Surgical Oncology, 2018, 117, 1493-1499.	0.8	5
58	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. Hpb, 2018, 20, 132-139.	0.1	23
59	Locally advanced pancreas cancer: Staging and goals of therapy. Surgery, 2018, 163, 1053-1062.	1.0	53
60	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. Journal of Surgical Oncology, 2018, 117, 1664-1671.	0.8	4
61	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery, 2018, 163, 318-323.	1.0	29
62	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Abdominal Radiology, 2018, 43, 351-363.	1.0	11
63	Development of a high risk pancreatic screening clinic using 3.0ÂT MRI. Familial Cancer, 2018, 17, 101-111.	0.9	20
64	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2018, 268, 610-619.	2.1	58
65	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. Surgery, 2018, 163, 1028-1034.	1.0	8
66	Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer, 2018, 18, 335.	1.1	271
67	Targeting of the Histone 3 Lysine 9 Methyltransferase Pathway in Krasâ€induced Cell Growth and Pancreatic Cancer. FASEB Journal, 2018, 32, 826.11.	0.2	0
68	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Laboratory Investigation, 2017, 97, 302-317.	1.7	30
69	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. Journal of Surgical Oncology, 2017, 116, 307-312.	0.8	21
70	A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. Journal of Gastrointestinal Surgery, 2017, 21, 1186-1191.	0.9	3
71	Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?. Journal of Gastrointestinal Surgery, 2017, 21, 1793-1803.	0.9	24
72	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. Practical Radiation Oncology, 2017, 7, e449-e455.	1.1	0

#	Article	IF	Citations
73	The prognostic utility of baseline alphaâ€fetoprotein for hepatocellular carcinoma patients. Journal of Surgical Oncology, 2017, 116, 831-840.	0.8	27
74	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Hpb, 2017, 19, 659-666.	0.1	84
75	Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.. Journal of Clinical Oncology, 2017, 35, 11503-11503.	0.8	9
76	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review.. Journal of Clinical Oncology, 2017, 35, 351-351.	0.8	0
77	Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. Journal of Clinical Oncology, 2017, 35, 442-442.	0.8	0
78	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database.. Journal of Clinical Oncology, 2017, 35, 447-447.	0.8	0
79	Minimally invasive hepatectomy conversions: An analysis of outcomes.. Journal of Clinical Oncology, 2017, 35, 430-430.	0.8	0
80	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 282-282.	0.8	0
81	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. Journal of Clinical Oncology, 2017, 35, e15766-e15766.	0.8	0
82	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Journal of Oncology Practice, 2016, 12, 915-923.	2.5	19
83	Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. Journal of Surgical Oncology, 2016, 114, 291-295.	0.8	16
84	Evolution of the Management of Resectable Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 772-778.	2.5	24
85	Plasma extracellular RNA profiles in healthy and cancer patients. Scientific Reports, 2016, 6, 19413.	1.6	224
86	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Annals of Surgical Oncology, 2016, 23, 912-920.	0.7	28
87	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. Journal of Surgical Oncology, 2016, 114, 581-586.	0.8	23
88	Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. Surgical Clinics of North America, 2016, 96, 1351-1370.	0.5	39
89	Replaced gastroduodenal artery: Added benefit of the â€œartery firstâ€•approach during pancreaticoduodenectomyâ€”A case report. International Journal of Surgery Case Reports, 2016, 23, 93-97.	0.2	9
90	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery, 2016, 159, 893-900.	1.0	114

#	Article	IF	Citations
91	Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. Molecular Cancer Therapeutics, 2016, 15, 985-997.	1.9	15
92	Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. Journal of Clinical Oncology, 2016, 34, 397-397.	0.8	5
93	Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 428-428.	0.8	2
94	Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. Journal of Clinical Oncology, 2016, 34, 400-400.	0.8	0
95	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	0.8	0
96	Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 443-443.	0.8	31
97	Surgical resection versus ablation for hepatocellular carcinoma â‰Â3Âcm: a population-based analysis. Hpb, 2015, 17, 896-901.	0.1	34
98	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. Hpb, 2015, 17, 1119-1123.	0.1	10
99	Use of neoadjuvant therapy in patients 75Âyears of age and older with pancreatic cancer. Surgery, 2015, 158, 1545-1555.	1.0	36
100	Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls. Lung Cancer, 2015, 90, 78-84.	0.9	38
101	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 1395-1403.	1.9	44
102	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	0.7	83
103	Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Cancer Research, 2015, 75, 3314-3326.	0.4	89
104	Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Cancer Research, 2015, 75, 3529-3542.	0.4	56
105	Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies.. Journal of Clinical Oncology, 2015, 33, 11095-11095.	0.8	3
106	Neoadjuvant therapy for localized pancreatic cancer: guiding principles. Journal of Gastrointestinal Oncology, 2015, 6, 418-29.	0.6	32
107	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. Journal of Clinical Oncology, 2015, 33, 353-353.	0.8	0
108	Genetic screening for patients with pancreatic cancer: Frequency of high-risk mutations.. Journal of Clinical Oncology, 2015, 33, e12526-e12526.	0.8	0

#	Article	IF	Citations
109	Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?. Oncologist, 2014, 19, 266-274.	1.9	183
110	Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 41-46.	0.3	44
111	Arterial resection at the time of pancreatectomy for cancer. Surgery, 2014, 155, 919-926.	1.0	94
112	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. Journal of Clinical Oncology, 2014, 32, 287-287.	0.8	8
113	CXCL12 Chemokine Expression Suppresses Human Pancreatic Cancer Growth and Metastasis. PLoS ONE, 2014, 9, e90400.	1.1	74
114	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. Journal of Clinical Oncology, 2014, 32, 131-131.	0.8	0
115	A pilot study identifying cancer-associated macrophage-like cells in the blood of cancer patients.. Journal of Clinical Oncology, 2014, 32, e22014-e22014.	0.8	0
116	Low cytokeratin- and low EpCAM-expressing circulating tumor cells in pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 11046-11046.	0.8	2
117	Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. Journal of Clinical Oncology, 2013, 31, e15082-e15082.	0.8	2
118	Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. Journal of Clinical Oncology, 2013, 31, 282-282.	0.8	0
119	Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, TPS4147-TPS4147.	0.8	1
120	Importance of Lean Body Mass in the Oncologic Patient. Nutrition in Clinical Practice, 2012, 27, 593-598.	1.1	65
121	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. Journal of Clinical Oncology, 2012, 30, 186-186.	0.8	0
122	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. Journal of Clinical Oncology, 2012, 30, 256-256.	0.8	0